IMR Press / CEOG / Volume 33 / Issue 1 / pii/2006010

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research

Prevalence and antibiotic susceptibility of genital Mycoplasma hominis and· Ureaplasma urealyticum in a university hospital in Turkey

Show Less
1 Department of Infectious Diseases and Clinical Microbiology, Izzet Baysal Medical Faculty, Abant lzzet Baysal University, Bolu (Turkey)
2 Department of Microbiology and Clinical Microbiology, Izzet Baysal Medical Faculty, Abant lzzet Baysal University, Bolu (Turkey)
3 Department of Obstetrics and Gynecology, Izzet Baysal Medical Faculty, Abant lzzet Baysal University, Bolu (Turkey)
Clin. Exp. Obstet. Gynecol. 2006, 33(1), 36–38;
Published: 10 March 2006
Abstract

This study aimed to assess the colonization prevalence and antibiotic susceptiblity of genital Ureaplasma urealyticum and Mycoplasma hominis in a teaching hospital, in Turkey. A total of 382 sexually active women with abnormal vaginal discharge were included in the study. Samples that were obtained with cotton swabs were microbiologically analyzed for U. urealyticum and M. hominis, together with antimicrobial susceptibility to doxycycline, ciprofloxacin, ofloxacin, erythromycin, josamycin, pristinamycin, and tetracycline Ureaplasma urealyticum was detected in 185 (48.4%) cultures, and M. hominis in 17 (4.4%). Eight (2.1 %) cultures were positive for both. Resistance of M. hominis to doxycycline, ciprofloxacin, ofloxacin, erytromycin, josamycin, pristinamycin and tetrascy-cline was 5.9%, 17.6%, 41.2%, 88.2%, 5.9%, 5.9% and 11.8%, respectively. Resistance to doxycycline, ciprofloxacin, ofloxacin, erytromycin, josamycin, pristinamycin and tetrascycline in U. urealyticum isolates was 1.6%, 40.5%, 58.4%, 54.0%, 1.6%, 8.1 % and 13.5%, respectively. Both U. urealyticum (94.1 %) and M. hominis (96.2) were most sensitive to josamycin, and most resistant to erytromycin (U. urealyticum 54.0%, M. hominis 88.2) and of loxacin (U. urealyticum 58.4%, M. hominis 41.2%). As a result, the rate of U. urealyticum and M. hominis was found to be 48.4% and 4.4%, respectively. We conclude that doxycy­cline may be used in empirical treatment of genital tract infections in sexually active women. 

Keywords
Mycoplasma hominis
Ureaplasma urealyticum
Prevalence
Antibiotic susceptibility.
Share
Back to top